DK210 (EGFR)
Phase 1Biologic
DK210 (EGFR) is one of 31 biologic programs targeting Locally Advanced. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
35 competitors in Locally Advanced
#DrugCompanyPhaseTrials
1Eloxatin
TevaApproved
Camptosar
PfizerApproved
Adrucil
EElorac, Inc.
Approved
Taxol
TevaPhase 3
Truqap
AstraZenecaPhase 3
Paraplatin
AAvyxa
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Keytruda
Merck & Co.Phase 2
Immunotherapy
Bristol-Myers SquibbPhase 3
Lenvima
EisaiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DK210 (EGFR). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- DDEKA Biosciences